Treatment of Active CLL with TP53 Mutation or del(17p)
The presence of a TP53 gene mutation or deletion of chromosome 17p — the locus encoding tumour protein p53 — defines a high-risk CLL subgroup that requires a specifically tailored front-line approach. Standard chemoimmunotherapy is not appropriate in this setting.
Clinical Scenario
Patient presents with active CLL harbouring a TP53 mutation or del(17p) of the tumour protein p53 locus. This molecular finding carries a poor prognosis irrespective of IGHV mutational status and directly determines the choice of front-line therapy.
Treatment Approach
Front-line management centres on targeted, non-chemotherapy-based therapy. Several regimens are recognised for this population, including options from the BTK inhibitor class as well as BCL-2 inhibitor-based combinations — the selection depends on patient-specific factors.
Full regimen options, eligibility criteria, and sequencing details are in the complete protocol →
References
- TP53 mutation or del(17p): ibrutinib or acalabrutinib or venetoclax plus obinutuzumab or venetoclax alone or idelalisib plus rituximab [III, A].
- Patients with TP53 mutation or del(17p) should receive front-line therapy with BTKis [III, A]; CIT is not an option due to the poor prognosis with this therapy independent from IGHV status.
- The phosphoinositide 3 kinase (PI3K) inhibitor idelalisib plus rituximab may be used in patients who are not eligible for any other therapies [III, A].
View source ↗